Cargando…
Glycol chitosan incorporated retinoic acid chlorochalcone (RACC) nanoparticles in the treatment of Osteosarcoma
BACKGROUND: Osteosarcoma is the most common of all the bone malignancies and accounts for 30-80 % of the primary skeletal sarcomas. The overall survival rate of patients with osteosarcoma is < 20 % suggesting poor prognosis. METHODS: The present study demonstrates the effect of retinoic acid chlo...
Autores principales: | Qin, Yan-Guo, Zhu, Lan-Yu, Wang, Chen-Yu, Zhang, Bo-Yan, Wang, Qing-Yu, Li, Rui-Yan, Liu, Zhen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501080/ https://www.ncbi.nlm.nih.gov/pubmed/26170203 http://dx.doi.org/10.1186/s12944-015-0068-4 |
Ejemplares similares
-
Retraction Note: Glycol chitosan incorporated retinoic acid chlorochalcone (RACC) nanoparticles in the treatment of Osteosarcoma
por: Qin, Yan-Guo, et al.
Publicado: (2020) -
Retinoic acid-incorporated glycol chitosan nanoparticles inhibit the expression of Ezh2 in U118 and U138 human glioma cells
por: LU, HU-CHEN, et al.
Publicado: (2016) -
Retinoic acid-incorporated glycol chitosan nanoparticles inhibit the expression of Ezh2 in U118 and U138 human glioma cells
por: LU, HU-CHEN, et al.
Publicado: (2015) -
Beyond 2020: converging crises demand integrated responses: Statement by the RACC International Advisory Committee following the RACC-12 International Forum
por: Falk, Jim, et al.
Publicado: (2020) -
Entamoeba histolytica RacC Selectively
Engages p21-Activated Kinase Effectors
por: Bosch, Dustin E., et al.
Publicado: (2014)